This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Deutsche Bank cuts AstraZeneca to 'sell' AN
Haleon Prices Offer of EUR750 Million, GBP300 Million Notes MT
The mood is getting heavier, but Taylor Swift is keeping watch Our Logo
3i Infrastructure cut; JPMorgan likes Rotork AN
Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary CI
Haleon Seeks M&A Opportunities CI
Transcript : Haleon plc Presents at Barclays 17th Annual Global Consumer Staples Conference, Sep-03-2024 02:15 PM
Haleon Launches Erectile Dysfunction Treatment Eroxon in US MT
Haleon Announces the Launch of Eroxon®?, the First and Only Fda Cleared Otc Gel for Erectile Dysfunction, Available for U.S. Pre Order Without A Prescription CI
Futura Medical's Eroxon to be available in US from October AN
AIM WINNERS & LOSERS: Futura Medica celebrates Eroxon launch in US AN
Haleon Plans October Launch for Futura Medical's Erectile Dysfunction Gel in US MT
Tate & Lyle picks former De Beers CFO to be its new CFO AN
Tate & Lyle's New CFO to Join mid-September MT
Market's Manic Monday morphs into Turnaround Tuesday Our Logo
Goldman Sachs Downgrades Haleon to Neutral, Lifts PT MT
Haleon adds former Tesco and M&S CFO Alan Stewart to board AN
Berenberg Initiates Haleon at Buy With $11.44 Price Target MT
Analyst recommendations: Amazon, Tesla, AMD, Kellanova, Nvidia... Our Logo
Haleon plc Announces Board and Committees Appointments CI
Liberum says sell Rio Tinto and Anglo American AN
Global stocks tumble as risk-averse mood deepens AN
European companies cut jobs as economy sputters RE
Haleon plc: Portfolio of blockbusters Our Logo
Haleon plc commences an Equity Buyback Plan for 913,000,000 shares, representing 10% of its issued share capital, under the authorization approved on May 8, 2024. CI
Chart Haleon plc
More charts
Logo Haleon plc
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Employees
25,408
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
3.931GBP
Average target price
3.865GBP
Spread / Average Target
-1.67%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. Haleon H1 Adjusted Earnings Up, Revenue Down
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW